HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

H-Phe-Ser-Leu-Leu-Arg-Tyr-NH2

the PAR-2 antagonist

Also Known As:

FSLLRY-NH2; FSLLRY-amide

Networked: 13 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - H-Phe-Ser-Leu-Leu-Arg-Tyr-NH2: 13

Experts

1.	Bao, Yanju: 3 articles (09/2015 - 04/2014)
2.	Hou, Wei: 3 articles (09/2015 - 04/2014)
3.	Hua, Baojin: 3 articles (09/2015 - 04/2014)
4.	Huang, Lei: 2 articles (10/2020 - 01/2020)
5.	Ocak, Umut: 2 articles (10/2020 - 01/2020)
6.	Zhang, John H: 2 articles (10/2020 - 01/2020)
7.	Gao, Yebo: 2 articles (09/2015 - 03/2015)
8.	Kong, Xiangying: 2 articles (09/2015 - 03/2015)
9.	Li, Conghuang: 2 articles (09/2015 - 04/2014)
10.	Yang, Liping: 2 articles (09/2015 - 03/2015)

Related Diseases

1.	Hyperalgesia 09/15/2015 - "Blocking spinal PAR2 by using FSLLRY-NH2 significantly attenuated the activities of PKCε/PKA signaling pathways and TRPV1 expression as well as mechanical and thermal hyperalgesia. " 04/01/2014 - "Subcutaneous administration of the PAR2 antagonist FSLLRY-NH2 almost completely abolished mechanical allodynia and thermal hyperalgesia but had no effects on spontaneous pain behavior in the rats with bone cancer. " 01/01/2017 - "Prostaglandin E2 and 15-deoxyΔ12,14-prostaglandin J2 were upregulated only on day 1. In contrast, mechanical allodynia was sensitive to FSLLRY-NH2 (protease-activated receptor PAR2 antagonist) and RN-1734 (TRPV4 antagonist). " 03/01/2016 - "The serine protease inhibitor camostat mesilate and the proteinase-activated receptor 2 (PAR2) antagonist FSLLRY-NH2 significantly inhibited oxaliplatin-induced mechanical allodynia. "
2.	Pain (Aches) 04/01/2014 - "Subcutaneous administration of the PAR2 antagonist FSLLRY-NH2 almost completely abolished mechanical allodynia and thermal hyperalgesia but had no effects on spontaneous pain behavior in the rats with bone cancer. " 03/01/2015 - "Our data indicate that the combination of morphine and FSLLRY-NH2 has potent analgesic effects on bone cancer pain and our findings may aid in design of new strategies for the treatment of bone cancer pain." 03/01/2015 - "The analgesic effects of intraperitoneal treatment with morphine and/or intrathecal with the PAR2 antagonist, FSLLRY-NH2, on bone cancer pain-related behaviors in rats were examined. "
3.	Neuralgia (Stump Neuralgia) 10/13/2011 - "FSLLRY-amide, a selective PAR2 antagonist, blocked paclitaxel-induced neuropathic pain behaviors in a dose- and time-dependent manner. " 01/01/2016 - "Also, we showed that blocking spinal PAR2 by intrathecal injection of FSLLRY-NH2 significantly inhibits neuropathic pain responses induced by mechanical and thermal stimulation whereas FSLLRY-NH2 decreases the protein expression of TRPV1 and TRPA1 as well as the levels of substance P and calcitonin gene-related peptide. "
4.	Bone Neoplasms (Bone Cancer) 04/01/2014 - "Subcutaneous administration of the PAR2 antagonist FSLLRY-NH2 almost completely abolished mechanical allodynia and thermal hyperalgesia but had no effects on spontaneous pain behavior in the rats with bone cancer. " 03/01/2015 - "Our data indicate that the combination of morphine and FSLLRY-NH2 has potent analgesic effects on bone cancer pain and our findings may aid in design of new strategies for the treatment of bone cancer pain." 03/01/2015 - "The analgesic effects of intraperitoneal treatment with morphine and/or intrathecal with the PAR2 antagonist, FSLLRY-NH2, on bone cancer pain-related behaviors in rats were examined. "
5.	Seizures (Absence Seizure) 10/01/2020 - "The effect of PAR-2 inhibitor FSLLRY-NH2 on neurocognitive functions was assessed by neurologic deficit score, number of seizures, and T-maze test, while hippocampal neuronal degeneration was evaluated by Fluoro-Jade C staining after ACA. "

Related Drugs and Biologics

1.	PAR-2 Receptor
2.	Proteinase-Activated Receptors
3.	Paclitaxel (Taxol)
4.	Serine Proteinase Inhibitors (Serine Protease Inhibitors)
5.	Calcitonin Gene-Related Peptide
6.	Dinoprostone (PGE2)
7.	Substance P
8.	Proteins (Proteins, Gene)
9.	Peptides (Polypeptides)
10.	Peptide Hydrolases (Proteases)

Related Therapies and Procedures

1.	Therapeutics
2.	Spinal Injections